BioCryst Pharmaceuticals (BCRX) reported Friday preliminary Q4 revenue of $130.8 million, up 40% year over year.
Analysts polled by FactSet expected $128.6 million.
The company said it expects full-year 2025 revenue between $540 million and $560 million. Analysts polled by FactSet expect $536.4 million.
Shares of the company fell 4.5% in recent trading.
Price: 7.69, Change: -0.36, Percent Change: -4.47
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.